Skip to main content
. Author manuscript; available in PMC: 2010 Oct 1.
Published in final edited form as: Int J Cancer. 2009 Oct 1;125(7):1728–1734. doi: 10.1002/ijc.24553

Figure 7.

Figure 7

A549 and H1650 cells were exposed to erlotinib (1μM for A549 or 0.1μM for H1650), transfected with PIAS3 expression construct or exposed to both erlotinib and PIAS3. Both erlotinib and PIAS3 transfection resulted in growth inhibition compared to control (p< 0.01); however a combination of erlotinib and PIAS3 was significantly more effective than single treatment (p < 0.01). Proliferation was measured by MTS assay and cell count (n=6, data reported as mean ± SE).